1,481
Views
90
CrossRef citations to date
0
Altmetric
Review Article

Pharmacotherapy in pregnancy; effect of ABC and SLC transporters on drug transport across the placenta and fetal drug exposure

, &
Pages 736-763 | Received 11 Jun 2012, Accepted 24 Jul 2012, Published online: 20 Sep 2012

References

  • Abduljalil K, Furness P, Johnson TN, Rostami-Hodjegan A, Soltani H. (2012). Anatomical, physiological and metabolic changes with gestational age during normal pregnancy: a database for parameters required in physiologically based pharmacokinetic modelling. Clin Pharmacokinet, 51, 365–396.
  • Agarwal S, Elmquist WF. (2012). Insight into the cooperation of P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) at the blood-brain barrier: a case study examining sorafenib efflux clearance. Mol Pharm, 9, 678–684.
  • Ahmadimoghaddam D, Hofman J, Zemankova L, Nachtigal P, Dolezelova E, Cerveny L, Ceckova M, Micuda S, Staud F. (2012). Synchronized activity of Organic Cation Transporter 3 (Oct3/SLC22A3) and Multidrug and Toxin Extrusion 1 (Mate1/SLC47A1) transporter in transplacental passage of MPP+ in rat. Toxicol Sci, 128, 471–481.
  • Aleksunes LM, Cui Y, Klaassen CD. (2008). Prominent expression of xenobiotic efflux transporters in mouse extraembryonic fetal membranes compared with placenta. Drug Metab Dispos, 36, 1960–1970.
  • Allikmets R, Schriml LM, Hutchinson A, Romano-Spica V, Dean M. (1998). A human placenta-specific ATP-binding cassette gene (ABCP) on chromosome 4q22 that is involved in multidrug resistance. Cancer Res, 58, 5337–5339.
  • Alnouti Y, Petrick JS, Klaassen CD. (2006). Tissue distribution and ontogeny of organic cation transporters in mice. Drug Metab Dispos, 34, 477–482.
  • Ambudkar SV, Kimchi-Sarfaty C, Sauna ZE, Gottesman MM. (2003). P-glycoprotein: from genomics to mechanism. Oncogene, 22, 7468–7485.
  • Ampola MG, Mahoney MJ, Nakamura E, Tanaka K. (1975). Prenatal therapy of a patient with vitamin-B12-responsive methylmalonic acidemia. N Engl J Med, 293, 313–317.
  • Atkinson DE, Brice-Bennett S, D’Souza SW. (2007). Antiepileptic medication during pregnancy: does fetal genotype affect outcome? Pediatr Res, 62, 120–127.
  • Atkinson DE, Greenwood SL, Sibley CP, Glazier JD, Fairbairn LJ. (2003). Role of MDR1 and MRP1 in trophoblast cells, elucidated using retroviral gene transfer. Am J Physiol, Cell Physiol, 285, C584–C591.
  • Audus KL. (1999). Controlling drug delivery across the placenta. Eur J Pharm Sci, 8, 161–165.
  • Bajoria R, Contractor SF. (1997). Effect of surface charge of small unilamellar liposomes on uptake and transfer of carboxyfluorescein across the perfused human term placenta. Pediatr Res, 42, 520–527.
  • Bajoria R, Contractor SF. (1997). Effect of the size of liposomes on the transfer and uptake of carboxyfluorescein by the perfused human term placenta. J Pharm Pharmacol, 49, 675–681.
  • Bajoria R, Fisk NM, Contractor SF. (1997). Liposomal thyroxine: a noninvasive model for transplacental fetal therapy. J Clin Endocrinol Metab, 82, 3271–3277.
  • Bajoria R, Sooranna SR, Contractor SF. (1997). Endocytotic uptake of small unilamellar liposomes by human trophoblast cells in culture. Hum Reprod, 12, 1343–1348.
  • Baldwin SA, Yao SY, Hyde RJ, Ng AM, Foppolo S, Barnes K, Ritzel MW, Cass CE, Young JD. (2005). Functional characterization of novel human and mouse equilibrative nucleoside transporters (hENT3 and mENT3) located in intracellular membranes. J Biol Chem, 280, 15880–15887.
  • Barakat NS, Omar SA, Ahmed AA. (2006). Carbamazepine uptake into rat brain following intra-olfactory transport. J Pharm Pharmacol, 58, 63–72.
  • Barzago MM, Bortolotti A, Stellari FF, Diomede L, Algeri M, Efrati S, Salmona M, Bonati M. (1996). Placental transfer of valproic acid after liposome encapsulation during in vitro human placenta perfusion. J Pharmacol Exp Ther, 277, 79–86.
  • Bawdon RE. (1998). The ex vivo human placental transfer of the anti-HIV nucleoside inhibitor abacavir and the protease inhibitor amprenavir. Infect Dis Obstet Gynecol, 6, 244–246.
  • Ben-Haroush A, Yogev Y, Hod M. (2004). Epidemiology of gestational diabetes mellitus and its association with Type 2 diabetes. Diabet Med, 21, 103–113.
  • Bera TK, Lee S, Salvatore G, Lee B, Pastan I. (2001). MRP8, a new member of ABC transporter superfamily, identified by EST database mining and gene prediction program, is highly expressed in breast cancer. Mol Med, 7, 509–516.
  • Bierman WF, Scheffer GL, Schoonderwoerd A, Jansen G, van Agtmael MA, Danner SA, Scheper RJ. (2010). Protease inhibitors atazanavir, lopinavir and ritonavir are potent blockers, but poor substrates, of ABC transporters in a broad panel of ABC transporter-overexpressing cell lines. J Antimicrob Chemother, 65, 1672–1680.
  • Bloom SL, Dias KM, Bawdon RE, Gilstrap LC 3rd. (1997). The maternal-fetal transfer of lamivudine in the ex vivo human placenta. Am J Obstet Gynecol, 176, 291–293.
  • Bode CJ, Jin H, Rytting E, Silverstein PS, Young AM, Audus KL. (2006). In vitro models for studying trophoblast transcellular transport. Methods Mol Med, 122, 225–239.
  • Bodó A, Bakos E, Szeri F, Váradi A, Sarkadi B. (2003). The role of multidrug transporters in drug availability, metabolism and toxicity. Toxicol Lett, 140-141, 133–143.
  • Bonati M, Bortolus R, Marchetti F, Romero M, Tognoni G. (1990). Drug use in pregnancy: an overview of epidemiological (drug utilization) studies. Eur J Clin Pharmacol, 38, 325–328.
  • Bousquet L, Pruvost A, Didier N, Farinotti R, Mabondzo A. (2008). Emtricitabine: Inhibitor and substrate of multidrug resistance associated protein. Eur J Pharm Sci, 35, 247–256.
  • Bremer S, Hoof T, Wilke M, Busche R, Scholte B, Riordan JR, Maass G, Tümmler B. (1992). Quantitative expression patterns of multidrug-resistance P-glycoprotein (MDR1) and differentially spliced cystic-fibrosis transmembrane-conductance regulator mRNA transcripts in human epithelia. Eur J Biochem, 206, 137–149.
  • Burckhardt BC, Burckhardt G. (2003). Transport of organic anions across the basolateral membrane of proximal tubule cells. Rev Physiol Biochem Pharmacol, 146, 95–158.
  • Carter AM, Enders AC. (2004). Comparative aspects of trophoblast development and placentation. Reprod Biol Endocrinol, 2, 46.
  • Cascorbi I. (2011). P-glycoprotein: tissue distribution, substrates, and functional consequences of genetic variations. Handb Exp Pharmacol, 261–283.
  • Ceckova-Novotna M, Pavek P, Staud F. (2006). P-glycoprotein in the placenta: expression, localization, regulation and function. Reprod Toxicol, 22, 400–410.
  • Ceckova M, Libra A, Pavek P, Nachtigal P, Brabec M, Fuchs R, Staud F. (2006). Expression and functional activity of breast cancer resistance protein (BCRP, ABCG2) transporter in the human choriocarcinoma cell line BeWo. Clin Exp Pharmacol Physiol, 33, 58–65.
  • Ciarimboli G. (2008). Organic cation transporters. Xenobiotica, 38, 936–971.
  • Coan PM, Angiolini E, Sandovici I, Burton GJ, Constância M, Fowden AL. (2008). Adaptations in placental nutrient transfer capacity to meet fetal growth demands depend on placental size in mice. J Physiol (Lond), 586, 4567–4576.
  • Coetzee EJ, Jackson WP. (1979). Metformin in management of pregnant insulin-independent diabetics. Diabetologia, 16, 241–245.
  • Coetzee EJ, Jackson WP. (1984). Oral hypoglycaemics in the first trimester and fetal outcome. S Afr Med J, 65, 635–637.
  • Coetzee EJ, Jackson WP. (1985). The management of non-insulin-dependent diabetes during pregnancy. Diabetes Res Clin Pract, 1, 281–287.
  • Cole SP, Bhardwaj G, Gerlach JH, Mackie JE, Grant CE, Almquist KC, Stewart AJ, Kurz EU, Duncan AM, Deeley RG. (1992). Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science, 258, 1650–1654.
  • Collier AC, Ganley NA, Tingle MD, Blumenstein M, Marvin KW, Paxton JW, Mitchell MD, Keelan JA. (2002). UDP-glucuronosyltransferase activity, expression and cellular localization in human placenta at term. Biochem Pharmacol, 63, 409–419.
  • Coustan DR. (2007). Pharmacological management of gestational diabetes: an overview. Diabetes Care, 30 Suppl 2, S206–S208.
  • Cygalova L, Ceckova M, Pavek P, Staud F. (2008). Role of breast cancer resistance protein (Bcrp/Abcg2) in fetal protection during gestation in rat. Toxicol Lett, 178, 176–180.
  • Cygalova LH, Hofman J, Ceckova M, Staud F. (2009). Transplacental pharmacokinetics of glyburide, rhodamine 123, and BODIPY FL prazosin: effect of drug efflux transporters and lipid solubility. J Pharmacol Exp Ther, 331, 1118–1125.
  • Daw JR, Hanley GE, Greyson DL, Morgan SG. (2011). Prescription drug use during pregnancy in developed countries: a systematic review. Pharmacoepidemiol Drug Saf, 20, 895–902.
  • De Cock KM, Fowler MG, Mercier E, de Vincenzi I, Saba J, Hoff E, Alnwick DJ, Rogers M, Shaffer N. (2000). Prevention of mother-to-child HIV transmission in resource-poor countries: translating research into policy and practice. JAMA, 283, 1175–1182.
  • Dean M, Annilo T. (2005). Evolution of the ATP-binding cassette (ABC) transporter superfamily in vertebrates. Annu Rev Genomics Hum Genet, 6, 123–142.
  • DeGorter MK, Kim RB. (2011). Use of transgenic and knockout mouse models to assess solute carrier transporter function. Clin Pharmacol Ther, 89, 612–616.
  • Dhuria SV, Hanson LR, Frey WH 2nd. (2010). Intranasal delivery to the central nervous system: mechanisms and experimental considerations. J Pharm Sci, 99, 1654–1673.
  • Doyle LA, Yang W, Abruzzo LV, Krogmann T, Gao Y, Rishi AK, Ross DD. (1998). A multidrug resistance transporter from human MCF-7 breast cancer cells. Proc Natl Acad Sci USA, 95, 15665–15670.
  • Durán JM, Peral MJ, Calonge ML, Ilundáin AA. (2005). OCTN3: A Na+-independent L-carnitine transporter in enterocytes basolateral membrane. J Cell Physiol, 202, 929–935.
  • Ekaratanawong S, Anzai N, Jutabha P, Miyazaki H, Noshiro R, Takeda M, Kanai Y, Sophasan S, Endou H. (2004). Human organic anion transporter 4 is a renal apical organic anion/dicarboxylate exchanger in the proximal tubules. J Pharmacol Sci, 94, 297–304.
  • Elliott BD, Langer O, Schenker S, Johnson RF. (1991). Insignificant transfer of glyburide occurs across the human placenta. Am J Obstet Gynecol, 165, 807–812.
  • Elliott BD, Schenker S, Langer O, Johnson R, Prihoda T. (1994). Comparative placental transport of oral hypoglycemic agents in humans: a model of human placental drug transfer. Am J Obstet Gynecol, 171, 653–660.
  • Enders AC, Blankenship TN. (1999). Comparative placental structure. Adv Drug Deliv Rev, 38, 3–15.
  • Enokizono J, Kusuhara H, Sugiyama Y. (2007). Effect of breast cancer resistance protein (Bcrp/Abcg2) on the disposition of phytoestrogens. Mol Pharmacol, 72, 967–975.
  • Errasti-Murugarren E, Díaz P, Godoy V, Riquelme G, Pastor-Anglada M. (2011). Expression and distribution of nucleoside transporter proteins in the human syncytiotrophoblast. Mol Pharmacol, 80, 809–817.
  • Eskandari S, Varshosaz J, Minaiyan M, Tabbakhian M. (2011). Brain delivery of valproic acid via intranasal administration of nanostructured lipid carriers: in vivo pharmacodynamic studies using rat electroshock model. Int J Nanomedicine, 6, 363–371.
  • Evseenko DA, Murthi P, Paxton JW, Reid G, Emerald BS, Mohankumar KM, Lobie PE, Brennecke SP, Kalionis B, Keelan JA. (2007). The ABC transporter BCRP/ABCG2 is a placental survival factor, and its expression is reduced in idiopathic human fetal growth restriction. FASEB J, 21, 3592–3605.
  • Evseenko DA, Paxton JW, Keelan JA. (2006). ABC drug transporter expression and functional activity in trophoblast-like cell lines and differentiating primary trophoblast. Am J Physiol Regul Integr Comp Physiol, 290, R1357–R1365.
  • Evseenko DA, Paxton JW, Keelan JA. (2007). The xenobiotic transporter ABCG2 plays a novel role in differentiation of trophoblast-like BeWo cells. Placenta, 28 Suppl A, S116–S120.
  • Feghali MN, Mattison DR. (2011). Clinical therapeutics in pregnancy. J Biomed Biotechnol, 2011, 783528.
  • Flynn PM, Mirochnick M, Shapiro DE, Bardeguez A, Rodman J, Robbins B, Huang S, Fiscus SA, Van Rompay KK, Rooney JF, Kearney B, Mofenson LM, Watts DH, Jean-Philippe P, Heckman B, Thorpe E Jr, Cotter A, Purswani M; PACTG 394 Study Team. (2011). Pharmacokinetics and safety of single-dose tenofovir disoproxil fumarate and emtricitabine in HIV-1-infected pregnant women and their infants. Antimicrob Agents Chemother, 55, 5914–5922.
  • Fraaij PL, Verweel G, van Rossum AM, Hartwig NG, Burger DM, de Groot R. (2007). Indinavir/low-dose ritonavir containing HAART in HIV-1 infected children has potent antiretroviral activity, but is associated with side effects and frequent discontinuation of treatment. Infection, 35, 186–189.
  • Fromm MF. (2000). P-glycoprotein: a defense mechanism limiting oral bioavailability and CNS accumulation of drugs. Int J Clin Pharmacol Ther, 38, 69–74.
  • DeGorter MK, Kim RB. (2011). Use of transgenic and knockout mouse models to assess solute carrier transporter function. Clin Pharmacol Ther, 89, 612–616.
  • Ganapathy V, Prasad PD. (2005). Role of transporters in placental transfer of drugs. Toxicol Appl Pharmacol, 207, 381–387.
  • Garcia-Garcia E, Andrieux K, Gil S, Couvreur P. (2005). Colloidal carriers and blood-brain barrier (BBB) translocation: a way to deliver drugs to the brain? Int J Pharm, 298, 274–292.
  • Gauster M, Desoye G, Tötsch M, Hiden U. (2012). The placenta and gestational diabetes mellitus. Curr Diab Rep, 12, 16–23.
  • Gedeon C, Anger G, Piquette-Miller M, Koren G. (2008). Breast cancer resistance protein: mediating the trans-placental transfer of glyburide across the human placenta. Placenta, 29, 39–43.
  • Gedeon C, Koren G. (2006). Designing pregnancy centered medications: drugs which do not cross the human placenta. Placenta, 27, 861–868.
  • Giacomini KM, Huang SM, Tweedie DJ, Benet LZ, Brouwer KL, Chu X, Dahlin A, Evers R, Fischer V, Hillgren KM, Hoffmaster KA, Ishikawa T, Keppler D, Kim RB, Lee CA, Niemi M, Polli JW, Sugiyama Y, Swaan PW, Ware JA, Wright SH, Yee SW, Zamek-Gliszczynski MJ, Zhang L; International Transporter Consortium. (2010). Membrane transporters in drug development. Nat Rev Drug Discov, 9, 215–236.
  • Gil S, Saura R, Forestier F, Farinotti R. (2005). P-glycoprotein expression of the human placenta during pregnancy. Placenta, 26, 268–270.
  • Gilligan J, Tong M, Longato L, de la Monte SM, Gundogan F. (2012). Precision-cut slice culture method for rat placenta. Placenta, 33, 67–72.
  • Glaeser H. (2011). Importance of P-glycoprotein for drug-drug interactions. Handb Exp Pharmacol, 285–297.
  • Gomez D, Martinez JA, Hanson LR, Frey WH 2nd, Toth CC. (2012). Intranasal treatment of neurodegenerative diseases and stroke. Front Biosci (Schol Ed), 4, 74–89.
  • Gorboulev V, Ulzheimer JC, Akhoundova A, Ulzheimer-Teuber I, Karbach U, Quester S, Baumann C, Lang F, Busch AE, Koepsell H. (1997). Cloning and characterization of two human polyspecific organic cation transporters. DNA Cell Biol, 16, 871–881.
  • Govindarajan R, Bakken AH, Hudkins KL, Lai Y, Casado FJ, Pastor-Anglada M, Tse CM, Hayashi J, Unadkat JD. (2007). In situ hybridization and immunolocalization of concentrative and equilibrative nucleoside transporters in the human intestine, liver, kidneys, and placenta. Am J Physiol Regul Integr Comp Physiol, 293, R1809–R1822.
  • Govindarajan R, Leung GP, Zhou M, Tse CM, Wang J, Unadkat JD. (2009). Facilitated mitochondrial import of antiviral and anticancer nucleoside drugs by human equilibrative nucleoside transporter-3. Am J Physiol Gastrointest Liver Physiol, 296, G910–G922.
  • Griffiths M, Beaumont N, Yao SY, Sundaram M, Boumah CE, Davies A, Kwong FY, Coe I, Cass CE, Young JD, Baldwin SA. (1997). Cloning of a human nucleoside transporter implicated in the cellular uptake of adenosine and chemotherapeutic drugs. Nat Med, 3, 89–93.
  • Griffiths M, Yao SY, Abidi F, Phillips SE, Cass CE, Young JD, Baldwin SA. (1997). Molecular cloning and characterization of a nitrobenzylthioinosine-insensitive (ei) equilibrative nucleoside transporter from human placenta. Biochem J, 328 (Pt 3), 739–743.
  • Grube M, Meyer Zu Schwabedissen H, Draber K, Präger D, Möritz KU, Linnemann K, Fusch C, Jedlitschky G, Kroemer HK. (2005). Expression, localization, and function of the carnitine transporter octn2 (slc22a5) in human placenta. Drug Metab Dispos, 33, 31–37.
  • Grube M, Reuther S, Meyer Zu Schwabedissen H, Köck K, Draber K, Ritter CA, Fusch C, Jedlitschky G, Kroemer HK. (2007). Organic anion transporting polypeptide 2B1 and breast cancer resistance protein interact in the transepithelial transport of steroid sulfates in human placenta. Drug Metab Dispos, 35, 30–35.
  • Gründemann D, Gorboulev V, Gambaryan S, Veyhl M, Koepsell H. (1994). Drug excretion mediated by a new prototype of polyspecific transporter. Nature, 372, 549–552.
  • Hahnova-Cygalova L, Ceckova M, Staud F. (2011). Fetoprotective activity of breast cancer resistance protein (BCRP, ABCG2): expression and function throughout pregnancy. Drug Metab Rev, 43, 53–68.
  • Havlir D, Cheeseman SH, McLaughlin M, Murphy R, Erice A, Spector SA, Greenough TC, Sullivan JL, Hall D, Myers M. (1995). High-dose nevirapine: safety, pharmacokinetics, and antiviral effect in patients with human immunodeficiency virus infection. J Infect Dis, 171, 537–545.
  • Hemauer SJ, Patrikeeva SL, Nanovskaya TN, Hankins GD, Ahmed MS. (2010). Role of human placental apical membrane transporters in the efflux of glyburide, rosiglitazone, and metformin. Am J Obstet Gynecol, 202, 383.e1–383.e7.
  • Hernández-Díaz S, Smith CR, Shen A, Mittendorf R, Hauser WA, Yerby M, Holmes LB; North American AED Pregnancy Registry; North American AED Pregnancy Registry. (2012). Comparative safety of antiepileptic drugs during pregnancy. Neurology, 78, 1692–1699.
  • Hiasa M, Matsumoto T, Komatsu T, Omote H, Moriyama Y. (2007). Functional characterization of testis-specific rodent multidrug and toxic compound extrusion 2, a class III MATE-type polyspecific H+/organic cation exporter. Am J Physiol, Cell Physiol, 293, C1437–C1444.
  • Higgins JW, Bedwell DW, Zamek-Gliszczynski MJ. (2012). Ablation of both organic cation transporter (OCT)1 and OCT2 alters metformin pharmacokinetics but has no effect on tissue drug exposure and pharmacodynamics. Drug Metab Dispos, 40, 1170–1177.
  • Hirano T, Yasuda S, Osaka Y, Asari M, Kobayashi M, Itagaki S, Iseki K. (2008). The inhibitory effects of fluoroquinolones on L-carnitine transport in placental cell line BeWo. Int J Pharm, 351, 113–118.
  • Hirt D, Urien S, Rey E, Arrivé E, Ekouévi DK, Coffié P, Leang SK, Lalsab S, Avit D, Nerrienet E, McIntyre J, Blanche S, Dabis F, Tréluyer JM. (2009). Population pharmacokinetics of emtricitabine in human immunodeficiency virus type 1-infected pregnant women and their neonates. Antimicrob Agents Chemother, 53, 1067–1073.
  • Holmes LB, Mittendorf R, Shen A, Smith CR, Hernandez-Diaz S. (2011). Fetal effects of anticonvulsant polytherapies: different risks from different drug combinations. Arch Neurol, 68, 1275–1281.
  • Hsu A, Granneman GR, Cao G, Carothers L, Japour A, El-Shourbagy T, Dennis S, Berg J, Erdman K, Leonard JM, Sun E. (1998). Pharmacokinetic interaction between ritonavir and indinavir in healthy volunteers. Antimicrob Agents Chemother, 42, 2784–2791.
  • Huang FD, Kung FL, Tseng YC, Chen MR, Chan HS, Lin CJ. (2009). Regulation of protein expression and function of octn2 in forskolin-induced syncytialization in BeWo Cells. Placenta, 30, 187–194.
  • Hui L, Bianchi DW. (2011). Prenatal pharmacotherapy for fetal anomalies: a 2011 update. Prenat Diagn, 31, 735–743.
  • Huisman MT, Smit JW, Wiltshire HR, Hoetelmans RM, Beijnen JH, Schinkel AH. (2001). P-glycoprotein limits oral availability, brain, and fetal penetration of saquinavir even with high doses of ritonavir. Mol Pharmacol, 59, 806–813.
  • Hutson JR, Garcia-Bournissen F, Davis A, Koren G. (2011). The human placental perfusion model: a systematic review and development of a model to predict in vivo transfer of therapeutic drugs. Clin Pharmacol Ther, 90, 67–76.
  • Hutson JR, Koren G, Matthews SG. (2010). Placental P-glycoprotein and breast cancer resistance protein: influence of polymorphisms on fetal drug exposure and physiology. Placenta, 31, 351–357.
  • Cha SH, Sekine T, Kusuhara H, Yu E, Kim JY, Kim DK, Sugiyama Y, Kanai Y, Endou H. (2000). Molecular cloning and characterization of multispecific organic anion transporter 4 expressed in the placenta. J Biol Chem, 275, 4507–4512.
  • Chappuy H, Tréluyer JM, Jullien V, Dimet J, Rey E, Fouché M, Firtion G, Pons G, Mandelbrot L. (2004). Maternal-fetal transfer and amniotic fluid accumulation of nucleoside analogue reverse transcriptase inhibitors in human immunodeficiency virus-infected pregnant women. Antimicrob Agents Chemother, 48, 4332–4336.
  • Ieiri I. (2012). Functional significance of genetic polymorphisms in P-glycoprotein (MDR1, ABCB1) and breast cancer resistance protein (BCRP, ABCG2). Drug Metab Pharmacokinet, 27, 85–105.
  • Illum L. (2000). Transport of drugs from the nasal cavity to the central nervous system. Eur J Pharm Sci, 11, 1–18.
  • Irvine L, Flynn RW, Libby G, Crombie IK, Evans JM. (2010). Drugs dispensed in primary care during pregnancy: a record-linkage analysis in Tayside, Scotland. Drug Saf, 33, 593–604.
  • Ishizaki T, Yokochi K, Chiba K, Tabuchi T, Wagatsuma T. (1981). Placental transfer of anticonvulsants (phenobarbital, phenytoin, valproic acid) and the elimination from neonates. Pediatr Pharmacol (New York), 1, 291–303.
  • Ito S. (2001). Transplacental treatment of fetal tachycardia: implications of drug transporting proteins in placenta. Semin Perinatol, 25, 196–201.
  • Jacqz-Aigrain E, Koren G. (2005). Effects of drugs on the fetus. Semin Fetal Neonatal Med, 10, 139–147.
  • Jedlitschky G, Leier I, Buchholz U, Center M, Keppler D. (1994). ATP-dependent transport of glutathione S-conjugates by the multidrug resistance-associated protein. Cancer Res, 54, 4833–4836.
  • Jonker JW, Buitelaar M, Wagenaar E, Van Der Valk MA, Scheffer GL, Scheper RJ, Plosch T, Kuipers F, Elferink RP, Rosing H, Beijnen JH, Schinkel AH. (2002). The breast cancer resistance protein protects against a major chlorophyll-derived dietary phototoxin and protoporphyria. Proc Natl Acad Sci USA, 99, 15649–15654.
  • Jonker JW, Smit JW, Brinkhuis RF, Maliepaard M, Beijnen JH, Schellens JH, Schinkel AH. (2000). Role of breast cancer resistance protein in the bioavailability and fetal penetration of topotecan. J Natl Cancer Inst, 92, 1651–1656.
  • Jonker JW, Wagenaar E, Mol CA, Buitelaar M, Koepsell H, Smit JW, Schinkel AH. (2001). Reduced hepatic uptake and intestinal excretion of organic cations in mice with a targeted disruption of the organic cation transporter 1 (Oct1 [Slc22a1]) gene. Mol Cell Biol, 21, 5471–5477.
  • Jonker JW, Wagenaar E, Van Eijl S, Schinkel AH. (2003). Deficiency in the organic cation transporters 1 and 2 (Oct1/Oct2 [Slc22a1/Slc22a2]) in mice abolishes renal secretion of organic cations. Mol Cell Biol, 23, 7902–7908.
  • Juliano RL, Ling V. (1976). A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim Biophys Acta, 455, 152–162.
  • Kaatz GW, McAleese F, Seo SM. (2005). Multidrug resistance in Staphylococcus aureus due to overexpression of a novel multidrug and toxin extrusion (MATE) transport protein. Antimicrob Agents Chemother, 49, 1857–1864.
  • Kacirova I, Grundmann M, Brozmanova H. (2010). Serum levels of lamotrigine during delivery in mothers and their infants. Epilepsy Res, 91, 161–165.
  • Kalabis GM, Kostaki A, Andrews MH, Petropoulos S, Gibb W, Matthews SG. (2005). Multidrug resistance phosphoglycoprotein (ABCB1) in the mouse placenta: fetal protection. Biol Reprod, 73, 591–597.
  • Karbach U, Kricke J, Meyer-Wentrup F, Gorboulev V, Volk C, Loffing-Cueni D, Kaissling B, Bachmann S, Koepsell H. (2000). Localization of organic cation transporters OCT1 and OCT2 in rat kidney. Am J Physiol Renal Physiol, 279, F679–F687.
  • Kartner N, Riordan JR, Ling V. (1983). Cell surface P-glycoprotein associated with multidrug resistance in mammalian cell lines. Science, 221, 1285–1288.
  • Kartner N, Shales M, Riordan JR, Ling V. (1983). Daunorubicin-resistant Chinese hamster ovary cells expressing multidrug resistance and a cell-surface P-glycoprotein. Cancer Res, 43, 4413–4419.
  • Kekuda R, Prasad PD, Wu X, Wang H, Fei YJ, Leibach FH, Ganapathy V. (1998). Cloning and functional characterization of a potential-sensitive, polyspecific organic cation transporter (OCT3) most abundantly expressed in placenta. J Biol Chem, 273, 15971–15979.
  • Keppler D. (2011). Multidrug resistance proteins (MRPs, ABCCs): importance for pathophysiology and drug therapy. Handb Exp Pharmacol, 299–323.
  • Kis O, Robillard K, Chan GN, Bendayan R. (2010). The complexities of antiretroviral drug-drug interactions: role of ABC and SLC transporters. Trends Pharmacol Sci, 31, 22–35.
  • Klaassen CD, Aleksunes LM. (2010). Xenobiotic, bile acid, and cholesterol transporters: function and regulation. Pharmacol Rev, 62, 1–96.
  • Kleinman CS, Copel JA, Weinstein EM, Santulli TV Jr, Hobbins JC. (1985). In utero diagnosis and treatment of fetal supraventricular tachycardia. Semin Perinatol, 9, 113–129.
  • Kobayashi D, Ieiri I, Hirota T, Takane H, Maegawa S, Kigawa J, Suzuki H, Nanba E, Oshimura M, Terakawa N, Otsubo K, Mine K, Sugiyama Y. (2005). Functional assessment of ABCG2 (BCRP) gene polymorphisms to protein expression in human placenta. Drug Metab Dispos, 33, 94–101.
  • Kobayashi D, Tamai I, Sai Y, Yoshida K, Wakayama T, Kido Y, Nezu J, Iseki S, Tsuji A. (2007). Transport of carnitine and acetylcarnitine by carnitine/organic cation transporter (OCTN) 2 and OCTN3 into epididymal spermatozoa. Reproduction, 134, 651–658.
  • Kodawara T, Masuda S, Wakasugi H, Uwai Y, Futami T, Saito H, Abe T, Inu K. (2002). Organic anion transporter oatp2-mediated interaction between digoxin and amiodarone in the rat liver. Pharm Res, 19, 738–743.
  • Koepsell H, Endou H. (2004). The SLC22 drug transporter family. Pflugers Arch, 447, 666–676.
  • Koepsell H, Lips K, Volk C. (2007). Polyspecific organic cation transporters: structure, function, physiological roles, and biopharmaceutical implications. Pharm Res, 24, 1227–1251.
  • Koepsell H, Schmitt BM, Gorboulev V. (2003). Organic cation transporters. Rev Physiol Biochem Pharmacol, 150, 36–90.
  • Kolwankar D, Glover DD, Ware JA, Tracy TS. (2005). Expression and function of ABCB1 and ABCG2 in human placental tissue. Drug Metab Dispos, 33, 524–529.
  • Koren G. (2001). Glyburide and fetal safety; transplacental pharmacokinetic considerations. Reprod Toxicol, 15, 227–229.
  • Kovo M, Haroutiunian S, Feldman N, Hoffman A, Glezerman M. (2008). Determination of metformin transfer across the human placenta using a dually perfused ex vivo placental cotyledon model. Eur J Obstet Gynecol Reprod Biol, 136, 29–33.
  • Kovo M, Kogman N, Ovadia O, Nakash I, Golan A, Hoffman A. (2008). Carrier-mediated transport of metformin across the human placenta determined by using the ex vivo perfusion of the placental cotyledon model. Prenat Diagn, 28, 544–548.
  • Kraemer J, Klein J, Lubetsky A, Koren G. (2006). Perfusion studies of glyburide transfer across the human placenta: implications for fetal safety. Am J Obstet Gynecol, 195, 270–274.
  • Lagas JS, Vlaming ML, Schinkel AH. (2009). Pharmacokinetic assessment of multiple ATP-binding cassette transporters: the power of combination knockout mice. Mol Interv, 9, 136–145.
  • Lahjouji K, Elimrani I, Lafond J, Leduc L, Qureshi IA, Mitchell GA. (2004). L-Carnitine transport in human placental brush-border membranes is mediated by the sodium-dependent organic cation transporter OCTN2. Am J Physiol, Cell Physiol, 287, C263–C269.
  • Lang TT, Young JD, Cass CE. (2004). Interactions of nucleoside analogs, caffeine, and nicotine with human concentrative nucleoside transporters 1 and 2 stably produced in a transport-defective human cell line. Mol Pharmacol, 65, 925–933.
  • Langer O, Conway DL, Berkus MD, Xenakis EM, Gonzales O. (2000). A comparison of glyburide and insulin in women with gestational diabetes mellitus. N Engl J Med, 343, 1134–1138.
  • Lankas GR, Wise LD, Cartwright ME, Pippert T, Umbenhauer DR. (1998). Placental P-glycoprotein deficiency enhances susceptibility to chemically induced birth defects in mice. Reprod Toxicol, 12, 457–463.
  • Leazer TM, Klaassen CD. (2003). The presence of xenobiotic transporters in rat placenta. Drug Metab Dispos, 31, 153–167.
  • Lee CA, Cook JA, Reyner EL, Smith DA. (2010). P-glycoprotein related drug interactions: clinical importance and a consideration of disease states. Expert Opin Drug Metab Toxicol, 6, 603–619.
  • Lee E, Maneno MK, Smith L, Weiss SR, Zuckerman IH, Wutoh AK, Xue Z. (2006). National patterns of medication use during pregnancy. Pharmacoepidemiol Drug Saf, 15, 537–545.
  • Lee NY, Sai Y, Nakashima E, Ohtsuki S, Kang YS. (2011). 6-Mercaptopurine transport by equilibrative nucleoside transporters in conditionally immortalized rat syncytiotrophoblast cell lines TR-TBTs. J Pharm Sci, 100, 3773–3782.
  • Lee WK, Choi JK, Cha SH. (2008). Co-localization and interaction of human organic anion transporter 4 with caveolin-1 in primary cultured human placental trophoblasts. Exp Mol Med, 40, 505–513.
  • Lee WK, Wolff NA, Thévenod F. (2009). Organic cation transporters: physiology, toxicology and special focus on ethidium as a novel substrate. Curr Drug Metab, 10, 617–631.
  • Leier I, Jedlitschky G, Buchholz U, Keppler D. (1994). Characterization of the ATP-dependent leukotriene C4 export carrier in mastocytoma cells. Eur J Biochem, 220, 599–606.
  • Leslie EM, Deeley RG, Cole SP. (2005). Multidrug resistance proteins: role of P-glycoprotein, MRP1, MRP2, and BCRP (ABCG2) in tissue defense. Toxicol Appl Pharmacol, 204, 216–237.
  • Lickteig AJ, Cheng X, Augustine LM, Klaassen CD, Cherrington NJ. (2008). Tissue distribution, ontogeny and induction of the transporters Multidrug and toxin extrusion (MATE) 1 and MATE2 mRNA expression levels in mice. Life Sci, 83, 59–64.
  • Liebes L, Mendoza S, Wilson D, Dancis J. (1990). Transfer of zidovudine (AZT) by human placenta. J Infect Dis, 161, 203–207.
  • Liley AW. (1963). Intrauterine transfusion of foetus in haemolytic disease. Br Med J, 2, 1107–1109.
  • Lin JH, Yamazaki M. (2003). Role of P-glycoprotein in pharmacokinetics: clinical implications. Clin Pharmacokinet, 42, 59–98.
  • Ling V, Baker RM. (1978). Dominance of colchicine resistance in hybrid CHO cells. Somatic Cell Genet, 4, 193–200.
  • Liu W, Okochi H, Benet LZ, Zhai SD. (2012). Sotalol permeability in cultured-cell, rat intestine, and PAMPA system. Pharm Res, 29, 1768–1774.
  • Liu X. (2011). Clinical trials of intranasal delivery for treating neurological disorders–a critical review. Expert Opin Drug Deliv, 8, 1681–1690.
  • Löscher W, Potschka H. (2005). Drug resistance in brain diseases and the role of drug efflux transporters. Nat Rev Neurosci, 6, 591–602.
  • Lu G, Abduljalil K, Jamei M, Johnson TN, Soltani H, Rostami-Hodjegan A. (2012). Physiologically-based Pharmacokinetic (PBPK) Models for Assessing the Kinetics of Xenobiotics during Pregnancy: Achievements and Shortcomings. Curr Drug Metab, 13, 695–720.
  • Lulic Jurjevic R, Podnar T, Vesel S. (2009). Diagnosis, clinical features, management, and post-natal follow-up of fetal tachycardias. Cardiol Young, 19, 486–493.
  • Maeno Y, Hirose A, Kanbe T, Hori D. (2009). Fetal arrhythmia: prenatal diagnosis and perinatal management. J Obstet Gynaecol Res, 35, 623–629.
  • Maher JM, Slitt AL, Cherrington NJ, Cheng X, Klaassen CD. (2005). Tissue distribution and hepatic and renal ontogeny of the multidrug resistance-associated protein (Mrp) family in mice. Drug Metab Dispos, 33, 947–955.
  • Malek A, Mattison DR. (2010). Drug development for use during pregnancy: impact of the placenta. Expert Rev Obstet Gynecol, 5, 437–454.
  • Mao Q. (2008). BCRP/ABCG2 in the placenta: expression, function and regulation. Pharm Res, 25, 1244–1255.
  • Martel F, Keating E. (2003). Uptake of 1-methyl-4-phenylpyridinium (MPP+) by the JAR human placental choriocarcinoma cell line: comparison with 5-hydroxytryptamine. Placenta, 24, 361–369.
  • Marzolini C, Rudin C, Decosterd LA, Telenti A, Schreyer A, Biollaz J, Buclin T; Swiss Mother + Child HIV Cohort Study. (2002). Transplacental passage of protease inhibitors at delivery. AIDS, 16, 889–893.
  • Masuda S, Terada T, Yonezawa A, Tanihara Y, Kishimoto K, Katsura T, Ogawa O, Inui K. (2006). Identification and functional characterization of a new human kidney-specific H+/organic cation antiporter, kidney-specific multidrug and toxin extrusion 2. J Am Soc Nephrol, 17, 2127–2135.
  • Mathias AA, Hitti J, Unadkat JD. (2005). P-glycoprotein and breast cancer resistance protein expression in human placentae of various gestational ages. Am J Physiol Regul Integr Comp Physiol, 289, R963–R969.
  • May K, Minarikova V, Linnemann K, Zygmunt M, Kroemer HK, Fusch C, Siegmund W. (2008). Role of the multidrug transporter proteins ABCB1 and ABCC2 in the diaplacental transport of talinolol in the term human placenta. Drug Metab Dispos, 36, 740–744.
  • McDevitt CA, Callaghan R. (2007). How can we best use structural information on P-glycoprotein to design inhibitors? Pharmacol Ther, 113, 429–441.
  • Menjoge AR, Rinderknecht AL, Navath RS, Faridnia M, Kim CJ, Romero R, Miller RK, Kannan RM. (2011). Transfer of PAMAM dendrimers across human placenta: prospects of its use as drug carrier during pregnancy. J Control Release, 150, 326–338.
  • Merchant SJ, Crocker IP, Baker PN, Tansinda D, Davidge ST, Guilbert LJ. (2004). Matrix metalloproteinase release from placental explants of pregnancies complicated by intrauterine growth restriction. J Soc Gynecol Investig, 11, 97–103.
  • Meyer zu Schwabedissen HE, Grube M, Dreisbach A, Jedlitschky G, Meissner K, Linnemann K, Fusch C, Ritter CA, Volker U, Kroemer HK. (2006). Epidermal growth factor-mediated activation of the map kinase cascade results in altered expression and function of ABCG2 (BCRP). Drug Metab Dispos, 34, 524–533.
  • Meyer Zu Schwabedissen HE, Grube M, Heydrich B, Linnemann K, Fusch C, Kroemer HK, Jedlitschky G. (2005a). Expression, localization, and function of MRP5 (ABCC5), a transporter for cyclic nucleotides, in human placenta and cultured human trophoblasts: effects of gestational age and cellular differentiation. Am J Pathol, 166, 39–48.
  • Meyer zu Schwabedissen HE, Jedlitschky G, Gratz M, Haenisch S, Linnemann K, Fusch C, Cascorbi I, Kroemer HK. (2005b). Variable expression of MRP2 (ABCC2) in human placenta: influence of gestational age and cellular differentiation. Drug Metab Dispos, 33, 896–904.
  • Minuesa G, Volk C, Molina-Arcas M, Gorboulev V, Erkizia I, Arndt P, Clotet B, Pastor-Anglada M, Koepsell H, Martinez-Picado J. (2009). Transport of lamivudine [(-)-beta-L-2′,3′-dideoxy-3′-thiacytidine] and high-affinity interaction of nucleoside reverse transcriptase inhibitors with human organic cation transporters 1, 2, and 3. J Pharmacol Exp Ther, 329, 252–261.
  • Mirochnick M, Fenton T, Gagnier P, Pav J, Gwynne M, Siminski S, Sperling RS, Beckerman K, Jimenez E, Yogev R, Spector SA, Sullivan JL. (1998). Pharmacokinetics of nevirapine in human immunodeficiency virus type 1-infected pregnant women and their neonates. Pediatric AIDS Clinical Trials Group Protocol 250 Team. J Infect Dis, 178, 368–374.
  • Mitra P, Audus KL. (2008). In vitro models and multidrug resistance mechanisms of the placental barrier. In Drug Absorption Studies (Ehrhardt C and Kim KJ eds) pp 368–396, Springer US.
  • Mitra P, Audus KL. (2010). MRP isoforms and BCRP mediate sulfate conjugate efflux out of BeWo cells. Int J Pharm, 384, 15–23.
  • Mittapalli RK, Vaidhyanathan S, Sane R, Elmquist WF. (2012). Impact of P-Glycoprotein (ABCB1) and Breast Cancer Resistance Protein (ABCG2) on the Brain Distribution of a Novel BRAF Inhibitor: Vemurafenib (PLX4032). J Pharmacol Exp Ther, 342, 33–40.
  • Miyake K, Mickley L, Litman T, Zhan Z, Robey R, Cristensen B, Brangi M, Greenberger L, Dean M, Fojo T, Bates SE. (1999). Molecular cloning of cDNAs which are highly overexpressed in mitoxantrone-resistant cells: demonstration of homology to ABC transport genes. Cancer Res, 59, 8–13.
  • Molina-Arcas M, Trigueros-Motos L, Casado FJ, Pastor-Anglada M. (2008). Physiological and pharmacological roles of nucleoside transporter proteins. Nucleosides Nucleotides Nucleic Acids, 27, 769–778.
  • Mölsä M, Heikkinen T, Hakkola J, Hakala K, Wallerman O, Wadelius M, Wadelius C, Laine K. (2005). Functional role of P-glycoprotein in the human blood-placental barrier. Clin Pharmacol Ther, 78, 123–131.
  • Moodley J, Moodley D, Pillay K, Coovadia H, Saba J, van Leeuwen R, Goodwin C, Harrigan PR, Moore KH, Stone C, Plumb R, Johnson MA. (1998). Pharmacokinetics and antiretroviral activity of lamivudine alone or when coadministered with zidovudine in human immunodeficiency virus type 1-infected pregnant women and their offspring. J Infect Dis, 178, 1327–1333.
  • Moore JL, Aggarwal P. (2012). Lamotrigine use in pregnancy. Expert Opin Pharmacother, 13, 1213–1216.
  • Morita Y, Kodama K, Shiota S, Mine T, Kataoka A, Mizushima T, Tsuchiya T. (1998). NorM, a putative multidrug efflux protein, of Vibrio parahaemolyticus and its homolog in Escherichia coli. Antimicrob Agents Chemother, 42, 1778–1782.
  • Müller F, Fromm MF. (2011). Transporter-mediated drug-drug interactions. Pharmacogenomics, 12, 1017–1037.
  • Musoke P, Guay LA, Bagenda D, Mirochnick M, Nakabiito C, Fleming T, Elliott T, Horton S, Dransfield K, Pav JW, Murarka A, Allen M, Fowler MG, Mofenson L, Hom D, Mmiro F, Jackson JB. (1999). A phase I/II study of the safety and pharmacokinetics of nevirapine in HIV-1-infected pregnant Ugandan women and their neonates (HIVNET 006). AIDS, 13, 479–486.
  • Myllynen P, Kummu M, Kangas T, Ilves M, Immonen E, Rysä J, Pirilä R, Lastumäki A, Vähäkangas KH. (2008). ABCG2/BCRP decreases the transfer of a food-born chemical carcinogen, 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP) in perfused term human placenta. Toxicol Appl Pharmacol, 232, 210–217.
  • Myllynen P, Pienimäki P, Vähäkangas K. (2005). Human placental perfusion method in the assessment of transplacental passage of antiepileptic drugs. Toxicol Appl Pharmacol, 207, 489–494.
  • Myllynen P, Vähäkangas K. (2002). An examination of whether human placental perfusion allows accurate prediction of placental drug transport: studies with diazepam. J Pharmacol Toxicol Methods, 48, 131–138.
  • Myllynen PK, Pienimäki PK, Vähäkangas KH. (2003). Transplacental passage of lamotrigine in a human placental perfusion system in vitro and in maternal and cord blood in vivo. Eur J Clin Pharmacol, 58, 677–682.
  • Mylona P, Hoyland JA, Sibley CP. (1999). Sites of mRNA expression of the cystic fibrosis (CF) and multidrug resistance (MDR1) genes in the human placenta of early pregnancy: No evidence for complementary expression. Placenta, 20, 493–496.
  • Nademanee K, Kannan R, Hendrickson J, Ookhtens M, Kay I, Singh BN. (1984). Amiodarone-digoxin interaction: clinical significance, time course of development, potential pharmacokinetic mechanisms and therapeutic implications. J Am Coll Cardiol, 4, 111–116.
  • Nagashige M, Ushigome F, Koyabu N, Hirata K, Kawabuchi M, Hirakawa T, Satoh S, Tsukimori K, Nakano H, Uchiumi T, Kuwano M, Ohtani H, Sawada Y. (2003). Basal membrane localization of MRP1 in human placental trophoblast. Placenta, 24, 951–958.
  • Nakamura H, Ushigome F, Koyabu N, Satoh S, Tsukimori K, Nakano H, Ohtani H, Sawada Y. (2002). Proton gradient-dependent transport of valproic acid in human placental brush-border membrane vesicles. Pharm Res, 19, 154–161.
  • Nanovskaya T, Nekhayeva I, Karunaratne N, Audus K, Hankins GD, Ahmed MS. (2005). Role of P-glycoprotein in transplacental transfer of methadone. Biochem Pharmacol, 69, 1869–1878.
  • Nanovskaya TN, Nekhayeva I, Hankins GD, Ahmed MS. (2006). Effect of human serum albumin on transplacental transfer of glyburide. Biochem Pharmacol, 72, 632–639.
  • Nanovskaya TN, Nekhayeva IA, Hankins GD, Ahmed MS. (2008). Transfer of methadone across the dually perfused preterm human placental lobule. Am J Obstet Gynecol, 198, 126.e1–126.e4.
  • Nanovskaya TN, Nekhayeva IA, Patrikeeva SL, Hankins GD, Ahmed MS. (2006). Transfer of metformin across the dually perfused human placental lobule. Am J Obstet Gynecol, 195, 1081–1085.
  • Natarajan K, Xie Y, Baer MR, Ross DD. (2012). Role of breast cancer resistance protein (BCRP/ABCG2) in cancer drug resistance. Biochem Pharmacol, 83, 1084–1103.
  • Nekhayeva IA, Nanovskaya TN, Deshmukh SV, Zharikova OL, Hankins GD, Ahmed MS. (2005). Bidirectional transfer of methadone across human placenta. Biochem Pharmacol, 69, 187–197.
  • Nies AT, Koepsell H, Damme K, Schwab M. (2011). Organic cation transporters (OCTs, MATEs), in vitro and in vivo evidence for the importance in drug therapy. Handb Exp Pharmacol, 105–167.
  • Nicholson W, Bolen S, Witkop CT, Neale D, Wilson L, Bass E. (2009). Benefits and risks of oral diabetes agents compared with insulin in women with gestational diabetes: a systematic review. Obstet Gynecol, 113, 193–205.
  • Nishikawa M, Iwano H, Yanagisawa R, Koike N, Inoue H, Yokota H. (2010). Placental transfer of conjugated bisphenol A and subsequent reactivation in the rat fetus. Environ Health Perspect, 118, 1196–1203.
  • Nishimura T, Seki Y, Sato K, Chishu T, Kose N, Terasaki T, Kang YS, Sai Y, Nakashima E. (2008). Enhancement of zidovudine uptake by dehydroepiandrosterone sulfate in rat syncytiotrophoblast cell line TR-TBT 18d-1. Drug Metab Dispos, 36, 2080–2085.
  • Novotna M, Libra A, Kopecky M, Pavek P, Fendrich Z, Semecky V, Staud F. (2004). P-glycoprotein expression and distribution in the rat placenta during pregnancy. Reprod Toxicol, 18, 785–792.
  • Nozawa T, Imai K, Nezu J, Tsuji A, Tamai I. (2004). Functional characterization of pH-sensitive organic anion transporting polypeptide OATP-B in human. J Pharmacol Exp Ther, 308, 438–445.
  • O’Hare MF, Murnaghan GA, Russell CJ, Leahey WJ, Varma MP, McDevitt DG. (1980). Sotalol as a hypotensive agent in pregnancy. Br J Obstet Gynaecol, 87, 814–820.
  • Okuda M, Saito H, Urakami Y, Takano M, Inui K. (1996). cDNA cloning and functional expression of a novel rat kidney organic cation transporter, OCT2. Biochem Biophys Res Commun, 224, 500–507.
  • Omote H, Hiasa M, Matsumoto T, Otsuka M, Moriyama Y. (2006). The MATE proteins as fundamental transporters of metabolic and xenobiotic organic cations. Trends Pharmacol Sci, 27, 587–593.
  • Otsuka M, Matsumoto T, Morimoto R, Arioka S, Omote H, Moriyama Y. (2005). A human transporter protein that mediates the final excretion step for toxic organic cations. Proc Natl Acad Sci USA, 102, 17923–17928.
  • Oudijk MA, Ruskamp JM, Ververs FF, Ambachtsheer EB, Stoutenbeek P, Visser GH, Meijboom EJ. (2003). Treatment of fetal tachycardia with sotalol: transplacental pharmacokinetics and pharmacodynamics. J Am Coll Cardiol, 42, 765–770.
  • Pascolo L, Fernetti C, Garcia-Mediavilla MV, Ostrow JD, Tiribelli C. (2001). Mechanisms for the transport of unconjugated bilirubin in human trophoblastic BeWo cells. FEBS Lett, 495, 94–99.
  • Pascolo L, Fernetti C, Pirulli D, Crovella S, Amoroso A, Tiribelli C. (2003). Effects of maturation on RNA transcription and protein expression of four MRP genes in human placenta and in BeWo cells. Biochem Biophys Res Commun, 303, 259–265.
  • Pavek P, Ceckova M, Staud F. (2009). Variation of drug kinetics in pregnancy. Curr Drug Metab, 10, 520–529.
  • Pávek P, Fendrich Z, Staud F, Malákova J, Brozmanová H, Láznícek M, Semecký V, Grundmann M, Palicka V. (2001). Influence of P-glycoprotein on the transplacental passage of cyclosporine. J Pharm Sci, 90, 1583–1592.
  • Pavek P, Staud F, Fendrich Z, Sklenarova H, Libra A, Novotna M, Kopecky M, Nobilis M, Semecky V. (2003). Examination of the functional activity of P-glycoprotein in the rat placental barrier using rhodamine 123. J Pharmacol Exp Ther, 305, 1239–1250.
  • Pollex E, Lubetsky A, Koren G. (2008). The role of placental breast cancer resistance protein in the efflux of glyburide across the human placenta. Placenta, 29, 743–747.
  • Pollex EK, Anger G, Hutson J, Koren G, Piquette-Miller M. (2010). Breast cancer resistance protein (BCRP)-mediated glyburide transport: effect of the C421A/Q141K BCRP single-nucleotide polymorphism. Drug Metab Dispos, 38, 740–744.
  • Pollex EK, Hutson JR. (2011). Genetic polymorphisms in placental transporters: implications for fetal drug exposure to oral antidiabetic agents. Expert Opin Drug Metab Toxicol, 7, 325–339.
  • Pradhan M, Manisha M, Singh R, Kapoor A. (2006). Amiodarone in treatment of fetal supraventricular tachycardia. A case report and review of literature. Fetal Diagn Ther, 21, 72–76.
  • De Domenico R, Faraci M, Hyseni E, Di Prima FA, Valenti O, Monte S, Giorgio E, Renda E. (2011). Increased nuchal traslucency in normal karyotype fetuses. J Prenat Med, 5, 23–26.
  • Rinaldo P, Matern D, Bennett MJ. (2002). Fatty acid oxidation disorders. Annu Rev Physiol, 64, 477–502.
  • Rizwan AN, Burckhardt G. (2007). Organic anion transporters of the SLC22 family: biopharmaceutical, physiological, and pathological roles. Pharm Res, 24, 450–470.
  • Rowan JA, Hague WM, Gao W, Battin MR, Moore MP; MiG Trial Investigators. (2008). Metformin versus insulin for the treatment of gestational diabetes. N Engl J Med, 358, 2003–2015.
  • Rytting E, Audus KL. (2007). Effects of low oxygen levels on the expression and function of transporter OCTN2 in BeWo cells. J Pharm Pharmacol, 59, 1095–1102.
  • Rytting E, Audus KL. (2008). Contributions of phosphorylation to regulation of OCTN2 uptake of carnitine are minimal in BeWo cells. Biochem Pharmacol, 75, 745–751.
  • Sai Y, Nishimura T, Shimpo S, Chishu T, Sato K, Kose N, Terasaki T, Mukai C, Kitagaki S, Miyakoshi N, Kang YS, Nakashima E. (2008). Characterization of the mechanism of zidovudine uptake by rat conditionally immortalized syncytiotrophoblast cell line TR-TBT. Pharm Res, 25, 1647–1653.
  • Saito J, Hirota T, Kikunaga N, Otsubo K, Ieiri I. (2011). Interindividual differences in placental expression of the SLC22A2 (OCT2) gene: relationship to epigenetic variations in the 5′-upstream regulatory region. J Pharm Sci, 100, 3875–3883.
  • Sata R, Ohtani H, Tsujimoto M, Murakami H, Koyabu N, Nakamura T, Uchiumi T, Kuwano M, Nagata H, Tsukimori K, Nakano H, Sawada Y. (2005). Functional analysis of organic cation transporter 3 expressed in human placenta. J Pharmacol Exp Ther, 315, 888–895.
  • Sato K, Sai Y, Nishimura T, Chishu T, Shimpo S, Kose N, Nakashima E. (2009). Influx mechanism of 2′,3′-dideoxyinosine and uridine at the blood-placenta barrier. Placenta, 30, 263–269.
  • Sato K, Sugawara J, Sato T, Mizutamari H, Suzuki T, Ito A, Mikkaichi T, Onogawa T, Tanemoto M, Unno M, Abe T, Okamura K. (2003). Expression of organic anion transporting polypeptide E (OATP-E) in human placenta. Placenta, 24, 144–148.
  • Satoh H, Yamashita F, Tsujimoto M, Murakami H, Koyabu N, Ohtani H, Sawada Y. (2005). Citrus juices inhibit the function of human organic anion-transporting polypeptide OATP-B. Drug Metab Dispos, 33, 518–523.
  • Serrano MA, Macias RI, Briz O, Monte MJ, Blazquez AG, Williamson C, Kubitz R, Marin JJ. (2007). Expression in human trophoblast and choriocarcinoma cell lines, BeWo, Jeg-3 and JAr of genes involved in the hepatobiliary-like excretory function of the placenta. Placenta, 28, 107–117.
  • Serrano MA, Macias RI, Vallejo M, Briz O, Bravo A, Pascual MJ, St-Pierre MV, Stieger B, Meier PJ, Marin JJ. (2003). Effect of ursodeoxycholic acid on the impairment induced by maternal cholestasis in the rat placenta-maternal liver tandem excretory pathway. J Pharmacol Exp Ther, 305, 515–524.
  • Shah A, Moon-Grady A, Bhogal N, Collins KK, Tacy T, Brook M, Hornberger LK. (2012). Effectiveness of sotalol as first-line therapy for fetal supraventricular tachyarrhythmias. Am J Cardiol, 109, 1614–1618.
  • Shekhawat P, Bennett MJ, Sadovsky Y, Nelson DM, Rakheja D, Strauss AW. (2003). Human placenta metabolizes fatty acids: implications for fetal fatty acid oxidation disorders and maternal liver diseases. Am J Physiol Endocrinol Metab, 284, E1098–E1105.
  • Shekhawat PS, Yang HS, Bennett MJ, Carter AL, Matern D, Tamai I, Ganapathy V. (2004). Carnitine content and expression of mitochondrial beta-oxidation enzymes in placentas of wild-type (OCTN2(+/+)) and OCTN2 Null (OCTN2(-/-)) Mice. Pediatr Res, 56, 323–328.
  • Schinkel AH. (1997). The physiological function of drug-transporting P-glycoproteins. Semin Cancer Biol, 8, 161–170.
  • Schmolling J, Renke K, Richter O, Pfeiffer K, Schlebusch H, Höller T. (2000). Digoxin, flecainide, and amiodarone transfer across the placenta and the effects of an elevated umbilical venous pressure on the transfer rate. Ther Drug Monit, 22, 582–588.
  • Sibley CP. (2009). Understanding placental nutrient transfer–why bother? New biomarkers of fetal growth. J Physiol (Lond), 587, 3431–3440.
  • Sibley CP, Glazier JD, Greenwood SL, Lacey H, Mynett K, Speake P, Jansson T, Johansson M, Powell TL. (2002). Regulation of placental transfer: the Na(+)/H(+) exchanger–a review. Placenta, 23 Suppl A, S39–S46.
  • Simon BJ, Kulanthaivel P, Burckhardt G, Ramamoorthy S, Leibach FH, Ganapathy V. (1992). Characterization of an ATP-driven H+ pump in human placental brush-border membrane vesicles. Biochem J, 287 (Pt 2), 423–430.
  • Singh GK. (2004). Management of Fetal Tachyarrhythmias. Curr Treat Options Cardiovasc Med, 6, 399–406.
  • Smit JW, Huisman MT, van Tellingen O, Wiltshire HR, Schinkel AH. (1999). Absence or pharmacological blocking of placental P-glycoprotein profoundly increases fetal drug exposure. J Clin Invest, 104, 1441–1447.
  • Spinnato JA, Shaver DC, Flinn GS, Sibai BM, Watson DL, Marin-Garcia J. (1984). Fetal supraventricular tachycardia: in utero therapy with digoxin and quinidine. Obstet Gynecol, 64, 730–735.
  • St-Pierre MV, Serrano MA, Macias RI, Dubs U, Hoechli M, Lauper U, Meier PJ, Marin JJ. (2000). Expression of members of the multidrug resistance protein family in human term placenta. Am J Physiol Regul Integr Comp Physiol, 279, R1495–R1503.
  • St-Pierre MV, Stallmach T, Freimoser Grundschober A, Dufour JF, Serrano MA, Marin JJ, Sugiyama Y, Meier PJ. (2004). Temporal expression profiles of organic anion transport proteins in placenta and fetal liver of the rat. Am J Physiol Regul Integr Comp Physiol, 287, R1505–R1516.
  • Staud F, Ceckova M, Micuda S, Pavek P. (2010). Expression and function of p-glycoprotein in normal tissues: effect on pharmacokinetics. Methods Mol Biol, 596, 199–222.
  • Staud F, Pavek P. (2005). Breast cancer resistance protein (BCRP/ABCG2). Int J Biochem Cell Biol, 37, 720–725.
  • Staud F, Vackova Z, Pospechova K, Pavek P, Ceckova M, Libra A, Cygalova L, Nachtigal P, Fendrich Z. (2006). Expression and transport activity of breast cancer resistance protein (Bcrp/Abcg2) in dually perfused rat placenta and HRP-1 cell line. J Pharmacol Exp Ther, 319, 53–62.
  • Storch CH, Theile D, Lindenmaier H, Haefeli WE, Weiss J. (2007). Comparison of the inhibitory activity of anti-HIV drugs on P-glycoprotein. Biochem Pharmacol, 73, 1573–1581.
  • Sudhakaran S, Ghabrial H, Nation RL, Kong DC, Gude NM, Angus PW, Rayner CR. (2005). Differential bidirectional transfer of indinavir in the isolated perfused human placenta. Antimicrob Agents Chemother, 49, 1023–1028.
  • Sudhakaran S, Rayner CR, Li J, Kong DC, Gude NM, Nation RL. (2008). Inhibition of placental P-glycoprotein: impact on indinavir transfer to the foetus. Br J Clin Pharmacol, 65, 667–673.
  • Sun M, Kingdom J, Baczyk D, Lye SJ, Matthews SG, Gibb W. (2006). Expression of the multidrug resistance P-glycoprotein, (ABCB1 glycoprotein) in the human placenta decreases with advancing gestation. Placenta, 27, 602–609.
  • Szakács G, Paterson JK, Ludwig JA, Booth-Genthe C, Gottesman MM. (2006). Targeting multidrug resistance in cancer. Nat Rev Drug Discov, 5, 219–234.
  • Tamai I, Ohashi R, Nezu J, Yabuuchi H, Oku A, Shimane M, Sai Y, Tsuji A. (1998). Molecular and functional identification of sodium ion-dependent, high affinity human carnitine transporter OCTN2. J Biol Chem, 273, 20378–20382.
  • Tamai I, Ohashi R, Nezu JI, Sai Y, Kobayashi D, Oku A, Shimane M, Tsuji A. (2000). Molecular and functional characterization of organic cation/carnitine transporter family in mice. J Biol Chem, 275, 40064–40072.
  • Tamai I, Yabuuchi H, Nezu J, Sai Y, Oku A, Shimane M, Tsuji A. (1997). Cloning and characterization of a novel human pH-dependent organic cation transporter, OCTN1. FEBS Lett, 419, 107–111.
  • Tamaki A, Ierano C, Szakacs G, Robey RW, Bates SE. (2011). The controversial role of ABC transporters in clinical oncology. Essays Biochem, 50, 209–232.
  • Taniguchi K, Wada M, Kohno K, Nakamura T, Kawabe T, Kawakami M, Kagotani K, Okumura K, Akiyama S, Kuwano M. (1996). A human canalicular multispecific organic anion transporter (cMOAT) gene is overexpressed in cisplatin-resistant human cancer cell lines with decreased drug accumulation. Cancer Res, 56, 4124–4129.
  • Terada T, Inui K. (2008). Physiological and pharmacokinetic roles of H+/organic cation antiporters (MATE/SLC47A). Biochem Pharmacol, 75, 1689–1696.
  • Terashita S, Dresser MJ, Zhang L, Gray AT, Yost SC, Giacomini KM. (1998). Molecular cloning and functional expression of a rabbit renal organic cation transporter. Biochim Biophys Acta, 1369, 1–6.
  • Tertti K, Ekblad U, Heikkinen T, Rahi M, Rönnemaa T, Laine K. (2010). The role of organic cation transporters (OCTs) in the transfer of metformin in the dually perfused human placenta. Eur J Pharm Sci, 39, 76–81.
  • Tertti K, Petsalo A, Niemi M, Ekblad U, Tolonen A, Rönnemaa T, Turpeinen M, Heikkinen T, Laine K. (2011). Transfer of repaglinide in the dually perfused human placenta and the role of organic anion transporting polypeptides (OATPs). Eur J Pharm Sci, 44, 181–186.
  • Thomas SH, Yates LM. (2012). Prescribing without evidence-pregnancy. Br J Clin Pharmacol, (In Press). DOI: 10.1111/j.1365-2125.2012.04332.x.
  • Tomson T, Battino D. (2009). Teratogenic effects of antiepileptic medications. Neurol Clin, 27, 993–1002.
  • Trezise AE, Romano PR, Gill DR, Hyde SC, Sepúlveda FV, Buchwald M, Higgins CF. (1992). The multidrug resistance and cystic fibrosis genes have complementary patterns of epithelial expression. EMBO J, 11, 4291–4303.
  • Tsuda M, Terada T, Asaka J, Ueba M, Katsura T, Inui K. (2007). Oppositely directed H+ gradient functions as a driving force of rat H+/organic cation antiporter MATE1. Am J Physiol Renal Physiol, 292, F593–F598.
  • Tsuda M, Terada T, Mizuno T, Katsura T, Shimakura J, Inui K. (2009). Targeted disruption of the multidrug and toxin extrusion 1 (mate1) gene in mice reduces renal secretion of metformin. Mol Pharmacol, 75, 1280–1286.
  • Ugele B, Bahn A, Rex-Haffner M. (2008). Functional differences in steroid sulfate uptake of organic anion transporter 4 (OAT4) and organic anion transporting polypeptide 2B1 (OATP2B1) in human placenta. J Steroid Biochem Mol Biol, 111, 1–6.
  • Ugele B, St-Pierre MV, Pihusch M, Bahn A, Hantschmann P. (2003). Characterization and identification of steroid sulfate transporters of human placenta. Am J Physiol Endocrinol Metab, 284, E390–E398.
  • Urakami Y, Akazawa M, Saito H, Okuda M, Inui K. (2002). cDNA cloning, functional characterization, and tissue distribution of an alternatively spliced variant of organic cation transporter hOCT2 predominantly expressed in the human kidney. J Am Soc Nephrol, 13, 1703–1710.
  • Urakami Y, Okuda M, Masuda S, Saito H, Inui KI. (1998). Functional characteristics and membrane localization of rat multispecific organic cation transporters, OCT1 and OCT2, mediating tubular secretion of cationic drugs. J Pharmacol Exp Ther, 287, 800–805.
  • Ushigome F, Takanaga H, Matsuo H, Tsukimori K, Nakano H, Ohtani H, Sawada Y. (2001). Uptake mechanism of valproic acid in human placental choriocarcinoma cell line (BeWo). Eur J Pharmacol, 417, 169–176.
  • Utoguchi N, Audus KL. (2000). Carrier-mediated transport of valproic acid in BeWo cells, a human trophoblast cell line. Int J Pharm, 195, 115–124.
  • Utoguchi N, Chandorkar GA, Avery M, Audus KL. (2000). Functional expression of P-glycoprotein in primary cultures of human cytotrophoblasts and BeWo cells. Reprod Toxicol, 14, 217–224.
  • Vähäkangas K, Myllynen P. (2006). Experimental methods to study human transplacental exposure to genotoxic agents. Mutat Res, 608, 129–135.
  • Vahakangas KH, Veid J, Karttunen V, Partanen HA, Sieppi E, Kummu M, Myllynen PK, Loikkanen J. (2011). The significance of ABC transporters in human placenta for the exposure of the fetus to xenobiotics. In Reproductive and Developmental Toxicology (Gupta R ed) pp 1051–1065, Academic Press, London.
  • Vajda FJ, Hitchcock AA, Graham J, O’Brien TJ, Lander CM, Eadie MJ. (2010). The teratogenic risk of antiepileptic drug polytherapy. Epilepsia, 51, 805–810.
  • van der Aa EM, Peereboom-Stegeman JH, Noordhoek J, Gribnau FW, Russel FG. (1998). Mechanisms of drug transfer across the human placenta. Pharm World Sci, 20, 139–148.
  • Verhaagh S, Schweifer N, Barlow DP, Zwart R. (1999). Cloning of the mouse and human solute carrier 22a3 (Slc22a3/SLC22A3) identifies a conserved cluster of three organic cation transporters on mouse chromosome 17 and human 6q26-q27. Genomics, 55, 209–218.
  • Viinikainen K, Heinonen S, Eriksson K, Kälviäinen R. (2006). Community-based, prospective, controlled study of obstetric and neonatal outcome of 179 pregnancies in women with epilepsy. Epilepsia, 47, 186–192.
  • Villain E, Vetter VL, Garcia JM, Herre J, Cifarelli A, Garson A Jr. (1990). Evolving concepts in the management of congenital junctional ectopic tachycardia. A multicenter study. Circulation, 81, 1544–1549.
  • Vlaming ML, Lagas JS, Schinkel AH. (2009). Physiological and pharmacological roles of ABCG2 (BCRP): recent findings in Abcg2 knockout mice. Adv Drug Deliv Rev, 61, 14–25.
  • Wang H, Wu X, Hudkins K, Mikheev A, Zhang H, Gupta A, Unadkat JD, Mao Q. (2006). Expression of the breast cancer resistance protein (Bcrp1/Abcg2) in tissues from pregnant mice: effects of pregnancy and correlations with nuclear receptors. Am J Physiol Endocrinol Metab, 291, E1295–E1304.
  • Waugh N, Royle P, Clar C, Henderson R, Cummins E, Hadden D, Lindsay R, Pearson D. (2010). Screening for hyperglycaemia in pregnancy: a rapid update for the National Screening Committee. Health Technol Assess, 14, 1–183.
  • Weiss J, Rose J, Storch CH, Ketabi-Kiyanvash N, Sauer A, Haefeli WE, Efferth T. (2007). Modulation of human BCRP (ABCG2) activity by anti-HIV drugs. J Antimicrob Chemother, 59, 238–245.
  • Wessler I, Roth E, Deutsch C, Brockerhoff P, Bittinger F, Kirkpatrick CJ, Kilbinger H. (2001). Release of non-neuronal acetylcholine from the isolated human placenta is mediated by organic cation transporters. Br J Pharmacol, 134, 951–956.
  • Westgren M. (2011). Fetal medicine and treatment. Handb Exp Pharmacol, 205, 271–283.
  • Westin UE, Boström E, Gråsjö J, Hammarlund-Udenaes M, Björk E. (2006). Direct nose-to-brain transfer of morphine after nasal administration to rats. Pharm Res, 23, 565–572.
  • Widerhorn J, Rubin JN, Frishman WH, Elkayam U. (1987). Cardiovascular drugs in pregnancy. Cardiol Clin, 5, 651–674.
  • Wright SH, Dantzler WH. (2004). Molecular and cellular physiology of renal organic cation and anion transport. Physiol Rev, 84, 987–1049.
  • Wu X, George RL, Huang W, Wang H, Conway SJ, Leibach FH, Ganapathy V. (2000). Structural and functional characteristics and tissue distribution pattern of rat OCTN1, an organic cation transporter, cloned from placenta. Biochim Biophys Acta, 1466, 315–327.
  • Wu X, Huang W, Ganapathy ME, Wang H, Kekuda R, Conway SJ, Leibach FH, Ganapathy V. (2000). Structure, function, and regional distribution of the organic cation transporter OCT3 in the kidney. Am J Physiol Renal Physiol, 279, F449–F458.
  • Wu X, Huang W, Prasad PD, Seth P, Rajan DP, Leibach FH, Chen J, Conway SJ, Ganapathy V. (1999). Functional characteristics and tissue distribution pattern of organic cation transporter 2 (OCTN2), an organic cation/carnitine transporter. J Pharmacol Exp Ther, 290, 1482–1492.
  • Wu X, Prasad PD, Leibach FH, Ganapathy V. (1998). cDNA sequence, transport function, and genomic organization of human OCTN2, a new member of the organic cation transporter family. Biochem Biophys Res Commun, 246, 589–595.
  • Xu J, Peng H, Zhang JT. (2007). Human multidrug transporter ABCG2, a target for sensitizing drug resistance in cancer chemotherapy. Curr Med Chem, 14, 689–701.
  • Yamamoto T, Kuniki K, Takekuma Y, Hirano T, Iseki K, Sugawara M. (2007). Ribavirin uptake by cultured human choriocarcinoma (BeWo) cells and Xenopus laevis oocytes expressing recombinant plasma membrane human nucleoside transporters. Eur J Pharmacol, 557, 1–8.
  • Yang T, Walker MC, Krewski D, Yang Q, Nimrod C, Garner P, Fraser W, Olatunbosun O, Wen SW. (2008). Maternal characteristics associated with pregnancy exposure to FDA category C, D, and X drugs in a Canadian population. Pharmacoepidemiol Drug Saf, 17, 270–277.
  • Yasuda S, Itagaki S, Hirano T, Iseki K. (2005). Expression level of ABCG2 in the placenta decreases from the mid stage to the end of gestation. Biosci Biotechnol Biochem, 69, 1871–1876.
  • Yeboah D, Sun M, Kingdom J, Baczyk D, Lye SJ, Matthews SG, Gibb W. (2006). Expression of breast cancer resistance protein (BCRP/ABCG2) in human placenta throughout gestation and at term before and after labor. Can J Physiol Pharmacol, 84, 1251–1258.
  • Yonezawa A, Inui K. (2011). Importance of the multidrug and toxin extrusion MATE/SLC47A family to pharmacokinetics, pharmacodynamics/toxicodynamics and pharmacogenomics. Br J Pharmacol, 164, 1817–1825.
  • Zhang L, Dresser MJ, Gray AT, Yost SC, Terashita S, Giacomini KM. (1997). Cloning and functional expression of a human liver organic cation transporter. Mol Pharmacol, 51, 913–921.
  • Zhang L, Dresser MJ, Chun JK, Babbitt PC, Giacomini KM. (1997). Cloning and functional characterization of a rat renal organic cation transporter isoform (rOCT1A). J Biol Chem, 272, 16548–16554.
  • Zhang L, Gorset W, Washington CB, Blaschke TF, Kroetz DL, Giacomini KM. (2000). Interactions of HIV protease inhibitors with a human organic cation transporter in a mammalian expression system. Drug Metab Dispos, 28, 329–334.
  • Zhang Y, Wang H, Unadkat JD, Mao Q. (2007). Breast cancer resistance protein 1 limits fetal distribution of nitrofurantoin in the pregnant mouse. Drug Metab Dispos, 35, 2154–2158.
  • Zhou L, Naraharisetti SB, Wang H, Unadkat JD, Hebert MF, Mao Q. (2008). The breast cancer resistance protein (Bcrp1/Abcg2) limits fetal distribution of glyburide in the pregnant mouse: an Obstetric-Fetal Pharmacology Research Unit Network and University of Washington Specialized Center of Research Study. Mol Pharmacol, 73, 949–959.
  • Zwart R, Verhaagh S, Buitelaar M, Popp-Snijders C, Barlow DP. (2001). Impaired activity of the extraneuronal monoamine transporter system known as uptake-2 in Orct3/Slc22a3-deficient mice. Mol Cell Biol, 21, 4188–4196.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.